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This study has determined the intracellular transport route of
Shiga-like toxin (Stx) and the highly related Shiga toxin in
human glomerular microvascular endothelial cells (GMVECs)
and mesangial cells. In addition, the effect of tumor necrosis
factor-a (TNF-a), which contributes to the pathogenesis of
hemolytic-uremic syndrome, was evaluated more profound.
Establishing the transport route will provide better
understanding of the cytotoxic effect of Stx on renal cells. For
our studies, we used receptor-binding B-subunit (StxB),
which is identical between Shiga toxin and Stx-1. The
transport route of StxB was studied by immunofluorescence
microscopy and biochemical assays that allow quantitative
analysis of retrograde transport from plasma membrane to
Golgi apparatus and endoplasmic reticulum (ER). In both cell
types, StxB was detergent-resistant membrane associated
and followed the retrograde route. TNF-a upregulated Gb3
expression in mesangial cells and GMVECs, without affecting
the efficiency of StxB transport to the ER. In conclusion, our
study shows that in human GMVECs and mesangial cells, StxB
follows the retrograde route to the Golgi apparatus and the
ER. TNF-a treatment increases the amount of cell-associated
StxB, but not retrograde transport as such, making it likely
that the strong TNF-a-induced sensitization of mesangial cells
and GMVECs for the toxic action of Stx is not due to a direct
effect on the intracellular trafficking of the toxin.
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Shiga-like toxins (Stxs) play a key role in the pathogenesis of
the diarrhoea-associated hemolytic-uremic syndrome (HUS).
Stx, produced by bacteria like Escherichia coli and Citrobacter
freundii,1 are exotoxins that have damaging effects on the
endothelial cells in the glomeruli and arterioles of the kidney.
This injury leads to cell death and the initiation of the
coagulation cascade. Consequently, the three classical features
of HUS will occur: acute renal failure, thrombocytopenia,
and hemolytic anemia. It is not yet known why Stxs have a
specific effect on the renal endothelium.
Stxs are highly similar to Shiga toxin from Shigella
dysenteriae. These toxins are all composed of a catalytic
A-subunit, and a receptor-binding homopentameric
B-subunit (StxB) that can bind to a specific functional
receptor. The A-subunits of Stx-1 and Shiga toxin differ in
only one amino acid, whereas the amino acid sequences of
the respective B-subunits are totally identical. In the
following, both toxins will be considered as equivalent
molecular entities. The receptor of Shiga toxin/Stx-1 is a
glycosphingolipid, called globotriaosylceramide, Gb3 or
CD77.2 After binding to this receptor, it is suggested that
Shiga toxin/Stx-1 can enter cells via both clathrin-dependent
and -independent endocytosis.3–6
Shiga toxin/Stx-1 induces different biological effects in
various human cell types on which its functional receptor is
present. In monocytes/macrophages, Shiga toxin/Stx-1has a
stimulating effect that consists of activation of the mitogen-
activated protein kinase system, nuclear translocation of
nuclear factor-kappa B, and secretion of cytokines like tumor
necrosis factor-a (TNF-a) and interleukin-6.7,8 In these cells
that are totally resistant to the cytotoxic function of Shiga
toxin/Stx-1, the toxin is effectively degraded in lysosomes
after having activated the cell.9 This transport route can also
be demonstrated in bovine intestinal epithelial cells.10
However, in toxin-sensitive cells such as cancer cell lines,
Shiga toxin/Stx-1 is able to escape lysosomal degradation and
can become cytotoxic.11 In these cells, Shiga toxin/Stx-1
follows a recently described pathway, termed the retrograde
transport route.
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Retrograde transport permits Shiga toxin/Stx-1 to bypass
the late endocytic pathway by trafficking directly from early/
recycling endosomes to the trans-Golgi network (TGN).12
This step is dependent on Rab6a0, SNARE complexes around
the heavy chain soluble N-ethymaleimide-sensitive factor
attachment proteins (SNAREs) syntaxin 16 and 5,13,14 the
tethering molecule golgin97,15 dynamin, clathrin,5,6 and the
potential clathrin adaptor epsinR.6 A correlation has also
been described between the retrograde trafficking of Shiga
toxin/Stx-1 at the early/recycling endosomes–TGN interface
and its association with detergent-resistant membranes
(DRMs). When Shiga toxin/Stx-1 is found in the DRM
fractions, for example in HeLa cells, the protein is targeted
into the retrograde route. In monocytes/macrophages, Shiga
toxin/Stx-1 is not associated with DRMs, and retrograde
transport is inefficient.9 From the TGN, Shiga toxin/Stx-1 is
transported to the endoplasmic reticulum (ER) using a
KDEL-receptor and coatomer protein complex I (COPI)-
independent pathway.16 After reaching the ER, Shiga toxin/
Stx-1 most likely uses the cellular retrotranslocation machin-
ery to transfer the catalytic A-subunit to the cytosol.17,18
The A-subunit functions as RNA N-glysosidase. In the
cytosol, it removes one adenine from the 28S rRNA of the
60S ribosomal unit and thereby inhibits the elongation factor
1-dependent aminoacyl-tRNA binding to ribosomes.19,20
This will lead to an inhibition of peptide elongation and
consequently an overall inhibition of protein synthesis.
The transport route of Shiga toxin/Stx-1 was never
investigated in primary renal cells, the main target for Stx-1
in humans. In this study, we used quantitative StxB-based
trafficking tools and immunofluorescence to analyze whether
Shiga toxin/Stx-1 was targeted to the retrograde route in
human glomerular and mesangial cells. Both cell types are
known to express Gb3, which can be upregulated by
cytokines like TNF-a.21–23 This cytokine can be found
elevated in serum of HUS patients.24 Also, Harel et al.25
found a kidney-specific induction of the TNF-a synthesis
after the injection of mice with Stx-1. Therefore, we have
studied the influence of TNF-a on the trafficking of StxB. As
expected, we found that TNF-a increases Gb3 expression and
thus, the quantity of cell-associated toxin. However, TNF-a
does not affect StxB association with DRMs and the efficiency
of retrograde StxB transport to the ER.
RESULTS
Gb3 extraction
To confirm the presence of Gb3 on human glomerular
microvascular endothelial cells (GMVECs) and mesangial
cells,22,23 neutral glycolipids were extracted from unstimu-
lated or TNF-a-stimulated cells, separated by thin-layer
chromatography, and Gb3 was specifically detected using an
overlay technique.9 The amount of Gb3 was quantified by
PhosphorImager (Table 1). As expected, GMVECs and
mesangial cells expressed Gb3. Expression levels in unstimu-
lated mesangial cells were comparable to HeLa cells, and
about two-fold higher than those found in unstimulated
GMVECs. Pretreatment with TNF-a resulted in a two-fold
increase of Gb3 levels in mesangial cells, and a five-fold
increase in GMVECs. Thus, after treatment with TNF-a,
GMVECs, and mesangial cells expressed similar Gb3 levels.
Transport to the Golgi apparatus
In HeLa cells, StxB traffics to the Golgi apparatus by
retrograde transport.9 To determine if StxB has access to
the retrograde route in human GMVECs and mesangial cells,
immunofluorescence experiments were performed with or
without pretreatment of the cells with TNF-a. After binding
and 4 or 24 h of internalization of Cy3-labeled StxB or StxB-
Glyc-KDEL, respectively, the cells were fixed, quenched,
permeabilized, and incubated with an antibody against the
Golgi marker CTR433. The intracellular distribution of StxB
was similar in TNF-a stimulated and unstimulated cells, and
in the following, only the immunofluorescence data on
unstimulated cells are shown.
After 4 h of internalization of Cy3-StxB, a significant
overlap between the Golgi-specific marker CTR433 (green)
and the StxB (red) was observed in GMVECs and mesangial
cells (Figure 1a), strongly suggesting that after 4 h, StxB was
targeted to the Golgi apparatus. Immunofluorescence
experiments were also performed after 24 h of internalization.
For this condition, a KDEL-tagged variant of StxB was used.
The KDEL peptide does not increase the efficiency of StxB
transport to the ER, but rather improves the ER retention of
the protein.26 Consistently, other studies showed that
interfering with KDEL-receptor function did not affect
retrograde transport of Stx to the ER.27 After 24 h of
internalization, no more overlap between the Golgi-marker
CTR433 (green) and Cy3-StxB-Glyc-KDEL (red) was ob-
served in GMVECs or mesangial cells (Figure 1b). The
observed staining pattern only partially overlapped with the
ER marker calnexin (not shown), and the exact identity of
the compartment in which StxB accumulated after 24 h
remains to be identified.
To confirm that StxB is transported to the Golgi
apparatus, a biochemical population-based approach was
used. The StxB-Sulf2 variant contains a tandem of protein
sulfation sites that are recognized by TGN-localized sulfo-
transferase, which catalyzes the post-translational transfer of
sulfate from the medium onto these sites.9 After binding on
Table 1 | Quantification of Gb3 expression
Cell types Gb3 (lg/106 cells)
HeLa cells 0.94
Mesangial cells 1.15
Mesangial cells+TNF-a 2.00
GMVEC 0.50
GMVEC+TNF-a 2.90
GMVEC, glomerular microvascular endothelial cell; TLC, thin-layer chromatography;
TNF, tumor necrosis factor.
After extraction of neutral glycolipids, Gb3 was detected by overlay and quantified
on TLC plates.
Standards were run in parallel.
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ice and internalization at 371C of StxB-Sulf2 for 4 h in
[35S]sulfate-containing medium, StxB-Sulf2 was immuno-
precipitated and sulfated protein was analyzed by autoradio-
graphy. Radiolabeled StxB-Sulf2 could be detected in
GMVECs and mesangial cells (Figure 2). HeLa cells were
used as positive control and human monocyte-derived
macrophages, in which retrograde transport cannot be
detected, as a negative control.9 Stimulation of GMVECs
and mesangial cells by TNF increased the sulfation signal,
reflecting the increased Gb3 expression under these condi-
tions (see Table 1).
Transport to the ER
In HeLa cells, StxB reaches the ER by retrograde trans-
port.9,12,26 To determine if StxB is also transported to the
ER in human GMVECs and mesangial cells, a modified
version of StxB, StxB-Glyc-KDEL, was used. StxB-Glyc-KDEL
contains a N-glycosylation site at the C-terminus, which is
glycosylated by ER-localized oligosaccharyl transferase,
allowing to monitor and quantify arrival in this compart-
ment.9,26 As discussed above, the KDEL tag ensures efficient
retention in the ER. Iodinated StxB-Glyc-KDEL was bound to
and internalized into GMVECs, mesangial cells, and HeLa
cells as a positive control. After 1, 4, or 24 h, glycosylated
StxB-Glyc-KDEL was detected and quantified by autoradio-
graphy after SDS-PAGE as the percentage of total cell-
associated StxB-Glyc-KDEL. It is important to indicate that
this assay system measures the glycosylation efficiency
independently of variations in receptor numbers, and thus,
allows comparison of the glycosylation efficiency – reflecting
retrograde transport to the ER – between different experi-
mental conditions.
Figure 3 shows representative gels from all three cell types
that were analyzed after preincubation or not with TNF-a.
The uppermost band, indicated by an arrow, represents the
glycosylation product, and the lowermost band is a
proteolytic cleavage product. All bands are visible in all
conditions. Quantification of the glycosylation bands is
shown in Table 2. In HeLa cells, glycosylation increases from
1.1% over 6.4–24.9% after, respectively, 1, 4, or 24 h. These
figures reproduce previously reported values,26 and reflect the
initial observation that glycosylation of StxB-Glyc-KDEL is
slower than its morphologically detected arrival in the ER
(immunofluorescence studies;26 electron microscopy stu-
dies28). This is likely due to inefficient recognition by
oligosaccharyl transferase of folded StxB-Glyc-KDEL and
possibly also to partial targeting of StxB-Glyc-KDEL to the
smooth ER.29 In mesangial cells, glycosylation efficiency is
systematically lower than in HeLa cells, even at the earliest
time points. This difference becomes particularly striking
after 24 h (Table 2). In GMVECs, the glycosylation efficiency
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Figure 1 | Immunofluorescence analysis of StxB transport to
the Golgi apparatus in human mesangial cells and GMVECs.
(a) Cy3-labeled StxB (red) was internalized for 4 h in human GMVECs
or in human mesangial cells. Cells were fixed and stained for the
Golgi marker CTR433 (green). StxB and CTR433 colocalize (yellow) in
both human GMVECs and human mesangial cells. (b) Cy3-labeled
StxB-Glyc-KDEL (red) was internalized for 24 h, and then fixed and
stained for the Golgi marker CTR433 in human GMVECs or mesangial
cells. No more accumulation of StxB in the Golgi region is observed.
Similar figures were obtained after 24 h incubation with Cy3-labeled
StxB (data not shown). Original magnification  63.
–TNF-
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Mesangial cells
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Figure 2 | Sulfation analysis of StxB transport to Golgi apparatus
in human GMVECs and human mesangial cells. Cells were
preincubated with or without TNF-a. After binding, StxB-Sulf2 was
internalized into GMVECs, mesangial cells, macrophages, and HeLa
cells in the presence of radioactive sulfate. Then cells were lysed, StxB
was immunoprecipitated and analyzed by gel electrophoresis.
Radiolabeled StxB-Sulf2 was revealed by autoradiography. Sulfated,
that is, TGN associated StxB-Sulf2 was detected in HeLa cells, GMVECs,
and mesangial cells.
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is comparable to HeLa at the earlier time points, even though
some decrease is already apparent after 4 h. After 24 h, the
glycosylation values observed on GMVECs are almost as
low as in mesangial cells (Table 2). Separated experiments
showed lack of glycosylation of StxB-Glyc-KDEL in human
monocyte-derived macrophages.
Strikingly, 24 h stimulation with TNF-a did not increase
retrograde transport efficiency in any of the analyzed cell
types at any of the analyzed time points (Table 2).
DRM association
It has previously been shown that efficient retrograde
transport of StxB correlates with efficient DRM association.9
To determine whether in mesangial cells and GMVECs, StxB
is also associated with DRMs, iodinated StxB-Glyc-KDEL was
bound to TNF-a treated or control cells on ice. Cells were
lysed in Triton X-100 buffer, DRMs were floated on
gradients, which were fractionated. DRMs were found at
the 5/30% interface, as described before.9 26 or 35% of cell-
associated StxB was found in DRMs in mesangial cells or
GMVECs, respectively (Figure 4), similar to the 30% that
were DRM associated in HeLa cells (not shown). After
preincubation with TNF-a for 24 h, no significant change in
percentages of StxB in the DRM fraction was observed.
DISCUSSION
During the development of HUS, most extensive tissue
damage occurs within the kidney.30 Proximal tubular cells are
exquisitely sensitive to Stx, undergoing apoptosis even
without prestimulation with TNF-a or lipopolysaccharide.31
Nevertheless, it is generally accepted that Stx-mediated
endothelial cell damage is the major event triggering the
development of HUS.30,32 It has been shown that cytokines
can upregulate the expression of Gb3 in both mesangial cells
and GMVECs.21–23 These findings have been confirmed in
our experiments with TNF-a. Stx does not affect mesangial
cell viability under basal conditions or after preincubation
with TNF-a, whereas protein synthesis is inhibited.22,23 In
unstimulated GMVEC, Stx does not inhibit cell viability and
protein synthesis, but GMVEC become highly sensitive for
Stx after stimulation with TNF-a.21
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Figure 3 | Glycosylation analysis of StxB transport to the ER. Cells
were incubated with or without TNF-a. After binding of iodinated
StxB-Glyc-KDEL on ice, the protein was internalized into (a) human
mesangial cells, (b) human GMVECs, and (c) HeLa cells for 1, 4, or
24 h. Then cells were lysed and lysates were analyzed by gel
electrophoresis. The arrow indicates the glycosylation product, that
is, ER-associated StxB. The middle band is non-glycosylated Shiga
toxin. The lower bands are proteolytic cleavage products.
Table 2 | Quantification of StxB retrograde transport to the ER
Glycosylation (%)
Incubation
time Cell type Control TNF-a
1 h GMVEC 1.670.9 (4) 1.570.6 (2)
Mesangial cells 0.670.1 (3) 0.570.2 (2)
HeLa cells 1.170.8 (3) 0.670.1 (2)
4 h GMVEC 5.573.5 (3) 5.071.1 (3)
Mesangial cells 3.873.3 (3) 1.970.6 (3)
HeLa cells 6.471.5 (4) 6.971.0 (3)
24 h GMVEC 9.272.8 (6) 10.373.0 (4)
Mesangial cells 7.471.2 (5) 7.271.7 (5)
HeLa cells 24.971.6 (6) 23.771.9 (5)
ER, endoplasmic reticulum; GMVEC, glomerular microvascular endothelial cell; TNF,
tumor necrosis factor.
After 24 h of preincubation with or without TNF-a, iodinated StxB-Glyc-KDEL was
bound to human GMVECs, human mesangial cells, and HeLa cells for 1, 4, or 24 h.
Then cells were lysed and lysates were analyzed by gel electrophoresis. Arrival in the
ER was quantified through the detection of StxB’s glycosylation.
Data given as means7s.e.m. (number of experiments in parentheses).
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Figure 4 | Analysis of StxB association with DRMs. After 24 h
preincubation with (dark gray) or without (light gray) TNF-a,
iodinated StxB-Glyc-KDEL was bound to (a) human GMVECs or
(b) human mesangial cells on ice. The cells were washed, lysed
in 1% Triton X-100 buffer, and DRMs were floated in Optiprep step
gradients. The gradients were fractionated and fractions were
counted in a gamma counter. StxB was readily detected in
the DRM fraction 2 in both cell types.
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In this study, we have demonstrated that the receptor
binding B-subunit of Shiga toxin/Stx-1 follows the retrograde
route in TNF-a stimulated and unstimulated mesangial cells
and GMVECs. The B-subunits are organized in a pentameric
form.33 The presence of the Shiga toxin A-subunit of cell
surface-bound toxin stimulates clathrin-dependent uptake of
the toxin.34 However, the trafficking route of the B-subunit
and the holotoxin is the same.11 Although the expression of
Gb3 is upregulated after incubation with TNF-a, and TNF-a-
treated cells bind more Shiga toxin/Stx-1 than unstimulated
cells, no change in the retrograde transport efficiency of Shiga
toxin/Stx-1 is observed. TNF-a therefore seems to increase
cytotoxicity of Shiga toxin/Stx-1 without affecting the
efficiency of the toxin’s intracellular trafficking. The relative
transport rate of Shiga toxin/Stx-1 remains unchanged.
Interestingly, it has also been shown that Stx-1 does not
influence the viability of mesangial cells and unstimulated
GMVECs,21,22 despite its retrograde transport in these cells,
as shown in this study. We conclude that whether or not a cell
is sensitive to Shiga toxin/Stx-1 does not only depend on
retrograde transport (see below), but also on additional
factors. One of these might be the amount of Shiga toxin/
Stx-1 that reaches the cytosol. Gb3 expression of unstimu-
lated GMVECs is much lower than the expression of Gb3 on
mesangial cells. When both are stimulated with TNF-a, Gb3
expression of GMVECs increases more and reaches higher
levels as in mesangial cells (Table 1). Under these conditions,
a threshold level of Shiga toxin/Stx-1 may be reached in the
ER that permits a cytotoxic amount of Stx to be transported
to the cytosol. Cellular processing of the uncleaved toxin by
the enzyme furin has also a role in this toxicity.4 It cannot be
excluded, however, that TNF-a has additional cellular effects
that also contribute to efficient intoxication of cells, such as
for example increasing retrotranslocation of toxin to the
cytosol.
When a toxic dose of Shiga toxin/Stx-1 reaches the cytosol
of a cell, ribosomes are inactivated and protein synthesis is
massively inhibited which leads to cell death.21 Classically, it
was thought that this was the only relevant biologic activity
of Shiga toxin/Stx-1.19,21,22 It is only recently that research in
this domain has focused on what is called the ‘ribotoxic stress
model’. When Shiga toxin/Stx-1 reaches the cytosol in a
subtoxic dose, for example, as in mesangial cells or
unstimulated GMVECs, only part of the ribosomes are
inactivated. The intact ribosomes are able to keep up with
protein synthesis so that cell viability is not affected. This
Shiga toxin/Stx-1-mediated damage to ribosomes may
generate a cellular-stress signaling response leading to
production of new ribosomes and proinflammatory cyto-
kines.7,35,36 In human umbilical vein endothelial cells, which
are comparable to GMVECs in that they are only sensitive to
Shiga toxin/Stx-1 after preincubation with TNF-a,37 stimula-
tion with a subtoxic dose of Stx-1 leads to expression of genes
that encode for chemokines and cytokines.38 This response is
also described in a monocytic cell line 7 and intestinal
epithelial cells.35,39 The ribotoxic stress model might be
applicable to renal cells, and thus contribute to the
pathogenesis of HUS.
In conclusion, we describe that in human GMVECs and
mesangial cells, Shiga toxin/Stx-1 is transported via the
retrograde route to the Golgi apparatus and ER. This study
thereby closes one of the remaining gaps in the under-
standing of the pathological process of HUS: it describes the
transport route of Shiga toxin/Stx-1 in its physiological target
cells, that is, human glomerular endothelial and mesangial
cells. Our study shows that TNF-a-induced sensitization of
renal cells must result from higher amounts of cell-associated
toxin rather than from stimulation of retrograde transport as
such, and thus, makes an important contribution to the
understanding of the cellular mechanisms of HUS.
MATERIALS AND METHODS
Cells and cell culture
Isolation of glomeruli, as well as purification, characterization, and
cell culture of human GMVECs and human mesangial cells was
performed as described by Van Setten et al.21,22 HeLa cells were
cultured as previously described by Johannes et al.26 Cells were used
for maximal 12 passages. All experiments in this paper were
performed at least three times on human GMVECs or mesangial
cells obtained from at least two different donors. The cells were
preincubated with a 100 ng/ml dose of TNF-a (Roche, Basel, Suisse).
This dose effectively induced expression of Gb3 on GMVECs
without affecting the viability of the cells.21
The human monocytes were obtained from blood of healthy
donors with their prior consent according to published procedures
by Faradji et al.40 Monocytes were differentiated into macrophages
using CSF1, as described by Falguie`res et al.9
Glycolipid extraction and thin-layer chromatography
Lipid extraction was performed as described by Falguie`res et al.9
according to the method of Bligh and Dyer.41 The isolated
glycolypids were spotted on high-performance thin-layer chroma-
tography plates (Science Inc., Agton Hights, IL, USA) and separated
with chloroform:methanol:water (65:25:4). The plates were dried
and incubated with STxB, polyclonal anti-STxB (obtained as
described previously9), and alkaline phosphatase-coupled antibodies
(Jackson Immunoresearch, West Grove, PA, USA). Reactive bands
were revealed with the use of ECF (Amersham Pharmacia Biotech,
Little Chalfont, UK) and quantified with a PhosphorImager (GE
Healthcare, Buckinghamshire, UK) using a standard Gb3 prepara-
tion as reference.
Immunofluorescence methods
Human GMVECs and mesangial cells were grown on gelatine-
coated glass coverslips and preincubated or not with TNF-a (100 ng/
ml) for 24 h. The cells were placed on ice and incubated with Cy3-
StxB or Cy3-StxB-Glyc-KDEL (obtained as described previously9)
for 30 min. Cy3 labeling of StxB labeling Cy3 was done according to
the manufacturer’s instructions (GE Healthcare). After washing with
cold (41C) culture medium, the cells were incubated with warm
(371C) complete culture medium (containing 20% fetal calf serum
instead of 10% new born calf serum and 10% human serum) for 4
or 24 h at 371C. Cells then were washed with phosphate-buffered
saline, fixed at room temperature for 15 min in 4% paraformalde-
hyde, quenched with ammonium chloride, permeabilized with 1%
saponine, incubated with the indicated primary (the antibody
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against Golgi-marker CTR433 was a kind gift from Dr M Bornens,
Institut Curie, France; calnexin-antibody is purchased from BD
Transduction Laboratories, Erebodegem, Belgium) and secondary
antibodies (anti-mouse FITC; purchased from Jackson Immunor-
esearch, West Grove, PA, USA), mounted, and viewed by confocal
microscopy (Leica Microsystems, Mannheim, Germany).
Iodination and DRM isolation
According to the manufacturer’s instructions for iodination, 150mg
of purified StxB-Glyc-KDEL was treated with 1 mCi iodine-125
(415 Ci/mg, GE Healthcare) on a single IODO-BEAD (Pierce
Biotechnology, Rockford, IL, USA). Non-incorporated iodine was
removed on PD10 gel filtration columns (GE Healthcare). StxB-
Glyc-KDEL was labeled to a specific activity of about 5000 c.p.m./ng.
DRMs were isolated on Optiprep (Sigma-Aldrich, St Louis, MO,
USA) gradients, as published.9 The DRMs were found at the 5/30%
interface.
Glycosylation assay
To obtain quantitative information on retrograde transport of StxB
to the ER, a modified version of StxB, StxB-Glyc-KDEL, was used
(purified as published9,26). Confluent GMVECs, mesangial cells, and
HeLa cells were preincubated with or without TNF-a (100 ng/ml) for
24 h. Binding of [125I]-labeled StxB-Glyc-KDEL (50 nM) was
performed for 30 min on ice in complete medium containing 20%
fetal calf serum. After incubation at 371C for the indicated periods of
time in the same culture medium, cells were washed with phosphate-
buffered saline and lysed in SDS sample buffer (187.5 mM Tris/HCl
pH 6.8, 6% SDS, 30% glycerol, 0.03% Phenol Red). Lysates were
analyzed by 10–20% gradient SDS-PAGE gels, and autoradiographs
were quantified by PhosphorImager analysis (GE Healthcare) using
ImageQuant software (GE Healthcare). The percentage of glycosy-
lated over total cell-associated StxB-Glyc-KDEL was determined.
Sulfation assay
A variant of StxB, StxB-Sulf2, was used to obtain quantitative
information on the passage of StxB into the Golgi apparatus
(purified as published9,12). Briefly, after 24 h of preincubation with
or without TNF-a (100 ng/ml), GMVECs, mesangial cells, and HeLa
cells were sulfate starved for 90 min. After binding of StxB-Sulf2 to
cells for 30 min on ice, the sulfate-starved cells were incubated for
4 h at 371C in 35SO4
2-containing medium (400 mCi/ml). The cells
were lysed in lysis buffer (1% Triton in phosphate-buffered saline
containing Protein Inhibitor Cocktail), and a post nuclear super-
natant was prepared. StxB-Sulf2 was immunoprecipitated with
monoclonal anti-StxB antibody 13C4 (obtained as described
previously9) and protein-G agarose beads. Washed precipitates were
boiled in SDS sample buffer, loaded on Tris-Trycine gels and
analyzed by autoradiography. Sulfation of StxB-Sulf2 was quantified
by PhosphorImager analysis (GE Healthcare) using ImageQuant
software (GE Healthcare). Global sulfation of endogenous proteins
and proteoglycans was determined by trichloracetic acid precipita-
tion of the immunoprecipitation supernatant. The precipitate was
retained on GF/C glass fiber filters (Whatmann, Maidstone, United
Kingdom) and radioactivity was counted in a liquid scintillation
counter.
ACKNOWLEDGMENTS
We thank M Bornens for the gift of antibody anti-CTR433 and D
Hanau (ETS Strasbourg) for the gift of the human monocytes. Also
we would like to thank T van der Velden for her excellent technical
assistance. This work was supported by grants from the Ligue
Nationale contre le Cancer, Association de Recherche Contre le
Cancer (nos. 5177 and 3105), Fondation de France, Action Concerte´e
Incitative – Jeunes chercheurs (no. 5233), Curie Institute (PIC
Vectroization) and by fellowships from Stichting Nijmeegs
UniversiteitsFonds, Studentenbudget UMC and FBW.
REFERENCES
1. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga
toxin-producing Escherichia coli infections. Clin Microbiol Rev
1998; 11: 450–479.
2. Lingwood CA, Law H, Richardson S et al. Glycolipid binding of purified
and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem
1987; 262: 8834–8839.
3. Nichols BJ, Kenworthy AK, Polishchuk RS et al. Rapid cycling of lipid raft
markers between the cell surface and Golgi complex. J Cell Biol 2001; 153:
529–541.
4. Sandvig K, van Deurs B. Endocytosis, intracellular transport, and cytotoxic
action of Shiga toxin and ricin. Physiol Rev 1996; 76: 949–966.
5. Lauvrak SU, Torgersen ML, Sandvig K. Efficient endosome-to-Golgi
transport of Shiga toxin is dependent on dynamin and clathrin. J Cell Sci
2004; 117: 2321–2331.
6. Saint-Pol A, Ye´lamos B, Amessou M et al. Clathrin adaptor epsinR is
required for retrograde sorting on early endosomal membranes. Dev Cell
2004; 6: 525–538.
7. Foster GH, Tesh VL. Shiga toxin 1-induced activation of c-Jun
NH(2)-terminal kinase and p38 in the human monocytic cell line
THP-1: possible involvement in the production of TNF-alpha. J Leukoc
Biol 2002; 71: 107–114.
8. van Setten PA, Monnens LA, Verstraten RG et al. Effects of verocytotoxin-1
on nonadherent human monocytes: binding characteristics,
protein synthesis, and induction of cytokine release. Blood 1996; 88:
174–183.
9. Falguie`res T, Mallard F, Baron CL et al. Targeting of Shiga toxin B-subunit
to retrograde transport route in association with detergent resistant
membranes. Mol Biol Cell 2001; 12: 2453–2468.
10. Hoey DE, Sharp L, Currie C et al. Verotoxin 1 binding to intestinal crypt
epithelial cells results in localization to lysosomes and abrogation of
toxicity. Cell Microbiol 2003; 5: 85–97.
11. Johannes L. The Shiga toxin B-subunit system: retrograde transport,
intracellular vectorization, and more. Am J Physiol Gastrointest Liver
Physiol 2002; 283: G1–G7.
12. Mallard F, Tenza D, Antony C et al. Direct pathway from early/recycling
endosomes to the Golgi apparatus revealed through the study of Shiga
toxin B-fragment transport. J Cell Biol 1998; 143: 973–990.
13. Mallard F, Tang BL, Galli T et al. Early/recycling endosomes-to-TGN
transport involves two SNARE complexes and a Rab6 isoform. J Cell Biol
2002; 156: 653–664.
14. Tai G, Lu L, Wang TL et al. Participation of syntaxin 5/Ykt6/GS28/GS15
SNARE complex in transport from the early/recycling endosome to the
TGN. Mol Biol Cell 2004; 15: 4011–4022.
15. Lu L, Tai G, Hong W. Autoantigen Golgin-97, an effector of Arl1 GTPase,
participates in traffic from the endosome to the trans-golgi network. Mol
Biol Cell 2004; 15: 4426–4443.
16. Smith DC, Lord JM, Roberts LM, Johannes L. Glycosphingolipids as toxin
receptors. Semin Cell Dev Biol 2004; 15: 397–408.
17. Hazes B, Read RJ. Accumulating evidence suggests that several
AB-toxins subvert the endoplasmic reticulum-associated protein
degradation pathway to enter target cells. Biochemistry 1997; 36:
11051–11054.
18. Yu M, Haslam DB. Shiga toxin is transported from the endoplasmic
reticulum following interaction with the luminal chaperone HEDJ/ERdj3.
Infect Immun 2005; 73: 2524–2532.
19. Endo Y, Tsurugi K, Yutsudo T et al. Site of action of a Vero toxin (VT2)
from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic
ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem
1998; 171: 45–50.
20. Obrig TG, Moran TP, Brown JE. The mode of action of Shiga toxin on
peptide elongation of eukaryotic protein synthesis. Biochem J 1987; 244:
287–294.
21. van Setten PA, van Hinsbergh VW, van der Velden TJ et al. Effects of TNF
alpha on verocytotoxin cytotoxicity in purified human glomerular
microvascular endothelial cells. Kidney Int 1997; 51: 1245–1256.
22. van Setten PA, van Hinsbergh VW, Van den Heuvel LP et al. Verocytotoxin
inhibits mitogenesis and protein synthesis in purified human glomerular
2090 Kidney International (2006) 70, 2085–2091
o r i g i n a l a r t i c l e M Warnier et al.: Shiga toxin transport route in glomerular endothelial and mesangial cells
mesangial cells without affecting cell viability: evidence for two distinct
mechanisms. J Am Soc Nephrol 1997; 8: 1877–1888.
23. Simon M, Cleary TG, Hernandez JD, Abboud HE. Shiga toxin 1 elicits
diverse biologic responses in mesangial cells. Kidney Int 1998; 54:
1117–1127.
24. Lopez EL, Contrini MM, Devoto S et al. Tumor necrosis factor
concentrations in hemolytic uremic syndrome patients and children with
bloody diarrhea in Argentina. Pediatr Infect Dis J 1995; 14: 594–598.
25. Harel Y, Silva M, Giroir B et al. A reporter transgene indicates renal-specific
induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible
involvement of TNF in hemolytic uremic syndrome. J Clin Invest 1993; 92:
2110–2116.
26. Johannes L, Tenza D, Antony C, Goud B. Retrograde transport of
KDEL-bearing B-fragment of Shiga toxin. J Biol Chem 1997; 272:
19554–19561.
27. Jackson ME, Simpson JC, Girod A et al. The KDEL retrieval system is
exploited by pseudomonas exotoxin A, but not by shiga-like toxin-1,
during retrograde transport from the golgi complex to the endoplasmic
reticulum. J Cell Sci 1999; 12: 467–475.
28. Kim JH, Johannes L, Goud B et al. Noninvasive measurement of the pH of
the endoplasmic reticulum at rest and during calcium release. Proc Natl
Acad Sci USA 1998; 95: 2997–3002.
29. White J, Johannes L, Mallard F et al. Rab6 coordinates a novel Golgi
to ER retrograde transport pathway in live cells. J Cell Biol 1999; 147:
743–759.
30. Ray PE, Liu XH. Pathogenesis of Shiga toxin-induced hemolytic uremic
syndrome. Pediatr Nephrol 2001; 16: 823–839.
31. Taguchi T, Uchida H, Kiyokawa N et al. Verotoxins induce apoptosis in
human renal tubular epithelium derived cells. Kidney Int 1998; 53:
1681–1688.
32. Proulx F, Seidman EG, Karpman D. Pathogenesis of Shiga toxin-associated
hemolytic uremic syndrome. Pediatr Res 2001; 50: 163–171.
33. Hagnerelle X, Plisson C, Lambert O et al. Two-dimensional structures of
Shiga toxin B-subunit and of a chimera bound to the glycolipid receptor
Gb3. J Struct Biol 2002; 139: 113–121.
34. Torgersen ML, Lauvrak SU, Sandvig K. The A-subunit of surface-bound
Shiga toxin stimulates clathrin-dependent uptake of the toxin. FEBS J
2005; 272: 4103–4113.
35. Colpoys WE, Cochran BH, Carducci TM, Thorpe CM. Shiga toxins activate
translational regulation pathways in intestinal epithelial cells. Cell Signal
2005; 17: 891–899.
36. Korcheva V, Wong J, Corless C et al. Administration of ricin induces a
severe inflammatory response via nonredundant stimulation of ERK, JNK,
and P38 MAPK and provides a mouse model of hemolytic uremic
syndrome. Am J Pathol 2005; 166: 323–339.
37. van de Kar NC, Monnens LA, Karmali MA, van Hinsbergh VW. Tumor
necrosis factor and interleukin-1 induce expression of the verocytotoxin
receptor globotriaosylceramide on human endothelial cells: implications
for the pathogenesis of the hemolytic uremic syndrome. Blood 1992; 80:
2755–2764.
38. Matussek A, Lauber J, Bergau A et al. Molecular and functional analysis of
Shiga toxin-induced response patterns in human vascular endothelial
cells. Blood 2003; 102: 1323–1332.
39. Thorpe CM, Smith WE, Hurley BP, Acheson DW. Shiga toxins induce,
superinduce, and stabilize a variety of C-X-C chemokine mRNAs in
intestinal epithelial cells, resulting in increased chemokine expression.
Infect Immun 2001; 69: 6140–6147.
40. Faradji A, Bohbot A, Schmitt-Goguel M et al. Large scale isolation of
human blood monocytes by continuous flow centrifugation
leukapheresis and counterflow centrifugation elutriation for adoptive
cellular immunotherapy in cancer patients. J Immunol Methods 1994; 174:
297–309.
41. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and
purification. Can J Biochem Biophys 1959; 37: 911–917.
Kidney International (2006) 70, 2085–2091 2091
M Warnier et al.: Shiga toxin transport route in glomerular endothelial and mesangial cells o r i g i n a l a r t i c l e
